DickSIM
Prima o poi....ci becco!
OCIO ,,,, potrebbe essere questione di giorni
ULTIMA CONTROLLATINA ,,,, che tutto funzioni al meglio
scusa ma controllo pure le mie..........
NicOx : Garufi ... e la Rivoluzione Pharma (1 Viewer)
- Creatore Discussione Yesod
- Data di Inizio
- Stato
scusa ma controllo pure le mie..........
DickSIM
Prima o poi....ci becco!
Non ci siamo capiti............non cambiate le carte in tavola che ci sono decine di testimoni in questo forum, silenti e non silenti.
A 100 euro userò i ceci.....se ci troveremo per la cena dei 30 euro i ceci al massimo li mangio e se i 30 euro saranno a causa di un OPA tra non so quando....sui ceci voglio vedervi a voi !!!!
......e ricordatevi che la fascia "CECI" è sino a 99.99 euro............quindi allenatevi le ginocchia sin d'ora......vi consiglio il "cammino di Compostela"
parla al singolare ...........grazie! io so bene come stanno le cose............ 
DickSIM
Prima o poi....ci becco!
Prepara il malloppo per la cena dei 30€€€€€€€€€€€€€€€ io procuro i ceci per il tuo transfer fino a qui in ginocchio come fantozzi a lraggiungimento dei
doc ma posti banconote di 100€ palesemente FALSE! io mi aspetto la news per i primi di Aprile.........
DickSIM
Prima o poi....ci becco!
DickSIM
Prima o poi....ci becco!
ESATTO !!!!!!
entro BREVISSSSSSSSIMO ,,,, cena dei 20 a BRESSO
a respirare la BRESSA NITRICA
DickSIM
Prima o poi....ci becco!
MARCH 20, 2009
Drug Maker Stiefel Labs Considers Selling Itself
Stiefel Laboratories Inc., a closely held pharmaceutical maker, is considering selling itself in a deal that could be worth several billion dollars, according to people familiar with the matter.
The potential sale has drawn interest from a number of major drug companies, including Johnson & Johnson, Novartis AG and GlaxoSmithKline PLC, these people said.
Stiefel, which makes anti-itch creams, acne treatments and other dermatological remedies, is hoping to fetch somewhere in the range of $3 billion to $4 billion, according to these people.
A spokeswoman for Stiefel said the company's board has not decided to sell the company and hasn't received any offers. "Like any business, if we received an offer it would be carefully considered," the spokeswoman said in an email.
Stiefel has been controlled for more than 160 years by the founding Stiefel family. Private-equity group Blackstone Group LP, which invested $500 million in the company in 2007, owns a substantial minority stake.
Stiefel, founded in Germany in 1847 and now based in Coral Gables, Fla., has annual revenue of about $1 billion, according to a person familiar with the company. Little financial information is available about Stiefel because it is privately held.
Stiefel has entertained offers in the past, but the recent spate of drug deals has renewed interest in the company.
Big pharmaceutical companies, faced with the pending expiration of patents on major drugs, are trying to diversify their businesses. Dermatology and the broader "aesthetic medicine" market is one they are increasingly interested in because of the aging global population.
But the economic downturn has tempered demand for many of these products and hit the share prices of some companies in the field. Medicis Pharmaceutical Corp., another maker of skin products, has seen its shares drop about 40% over the past year, for example.
After several generations of ownership, it's not clear why the Stiefel family would want to sell in such an environment.
Charles Stiefel, the company's chief executive and chairman, has expanded the company in recent years through several acquisitions. Stiefel paid about $605 million to acquire Connetics Corp., a drug company specialized in dermatology, in 2006. Last year, Stiefel bought Barrier Therapeutics Inc. for about $150 millio
Drug Maker Stiefel Labs Considers Selling Itself
Stiefel Laboratories Inc., a closely held pharmaceutical maker, is considering selling itself in a deal that could be worth several billion dollars, according to people familiar with the matter.
The potential sale has drawn interest from a number of major drug companies, including Johnson & Johnson, Novartis AG and GlaxoSmithKline PLC, these people said.
Stiefel, which makes anti-itch creams, acne treatments and other dermatological remedies, is hoping to fetch somewhere in the range of $3 billion to $4 billion, according to these people.
A spokeswoman for Stiefel said the company's board has not decided to sell the company and hasn't received any offers. "Like any business, if we received an offer it would be carefully considered," the spokeswoman said in an email.
Stiefel has been controlled for more than 160 years by the founding Stiefel family. Private-equity group Blackstone Group LP, which invested $500 million in the company in 2007, owns a substantial minority stake.
Stiefel, founded in Germany in 1847 and now based in Coral Gables, Fla., has annual revenue of about $1 billion, according to a person familiar with the company. Little financial information is available about Stiefel because it is privately held.
Stiefel has entertained offers in the past, but the recent spate of drug deals has renewed interest in the company.
Big pharmaceutical companies, faced with the pending expiration of patents on major drugs, are trying to diversify their businesses. Dermatology and the broader "aesthetic medicine" market is one they are increasingly interested in because of the aging global population.
But the economic downturn has tempered demand for many of these products and hit the share prices of some companies in the field. Medicis Pharmaceutical Corp., another maker of skin products, has seen its shares drop about 40% over the past year, for example.
After several generations of ownership, it's not clear why the Stiefel family would want to sell in such an environment.
Charles Stiefel, the company's chief executive and chairman, has expanded the company in recent years through several acquisitions. Stiefel paid about $605 million to acquire Connetics Corp., a drug company specialized in dermatology, in 2006. Last year, Stiefel bought Barrier Therapeutics Inc. for about $150 millio
DickSIM
Prima o poi....ci becco!
Bayer shares soar as FDA panel backs Xarelto
March 20, 2009 — 10:34am ET
An expert FDA panel has voted 15-to-2 in favor of short-term use of Xarelto (rivaroxaban), which is being developed by Bayer and Johnson & Johnson. Xarelto stops blood clots from forming after hip and knee replacements. The news sent Bayer's stock soaring 6.9 percent this morning.
The drug has already been approved for short-term use in Europe, and approval for that indication in the U.S. could bring in hundreds of millions in sales. However, Xarelto is projected to bring in as much as $6.8 billion in annual sales if approved for long-term use. "The real money lies in treating millions of chronic patients for stroke prevention and post-acute coronary syndrome," Rick Wise, an analyst with Leerink Swann, told The New York Times. The companies are still awaiting trial data on long-term use of the drug, which is expected in 2010.
If approved for long-term use, Xarelto could supplant warfarin, the dominant anti-clotting drug. In clinical trials, Xarelto was better than a comparative drug at preventing blood clots but increased major bleeding incidents among the patients taking the therapy. Undoubtedly, FDA will carefully consider risk-benefit ratio before approving Xarelto for long-term use.
March 20, 2009 — 10:34am ET
An expert FDA panel has voted 15-to-2 in favor of short-term use of Xarelto (rivaroxaban), which is being developed by Bayer and Johnson & Johnson. Xarelto stops blood clots from forming after hip and knee replacements. The news sent Bayer's stock soaring 6.9 percent this morning.
The drug has already been approved for short-term use in Europe, and approval for that indication in the U.S. could bring in hundreds of millions in sales. However, Xarelto is projected to bring in as much as $6.8 billion in annual sales if approved for long-term use. "The real money lies in treating millions of chronic patients for stroke prevention and post-acute coronary syndrome," Rick Wise, an analyst with Leerink Swann, told The New York Times. The companies are still awaiting trial data on long-term use of the drug, which is expected in 2010.
If approved for long-term use, Xarelto could supplant warfarin, the dominant anti-clotting drug. In clinical trials, Xarelto was better than a comparative drug at preventing blood clots but increased major bleeding incidents among the patients taking the therapy. Undoubtedly, FDA will carefully consider risk-benefit ratio before approving Xarelto for long-term use.
- Stato